- Dosing for Lexaria’s ambitious and most comprehensive clinical study, HYPER-H21-4, was successfully completed in July 2022, with newly analyzed results now emerging
- Its latest findings bring the company closer to its upcoming FDA Phase 1b study while also explaining the patented DehydraTECH-(TM)-processed CBD interaction with the sympatho-chromaffin system via catestatin modulation
- Lexaria’s management is optimistic that DehyraTECH-CBD and its effectiveness in modulating catestatin levels could become a significant value enhancer should it eventually enter the marketplace as an approved hypertension treatment
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, kicked off its human clinical study, HYPER-H21-1 in 2021, focused on testing its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the potential use as a hypertension treatment alternative (https://ibn.fm/hdVQ9). On July 27, 2022, the company announced that the dosing for its HYPER-H21-4 multi-week human clinical study was successfully completed, with no serious adverse events resulting from the dosing (https://ibn.fm/IZTUN).
This safety-related outcome – no serious adverse events – is generally speaking the desired primary outcome of Lexaria’s upcoming Phase 1b FDA-registered study.
Designed to enhance Lexaria’s probability of success toward an Investigational New Drug (“IND”) application filing for the U.S. Food and Drug Administration (“FDA”) approval, HYPER-H21-4 was the most comprehensive clinical study ever undertaken by Lexaria, with many types of analysis performed. Its latest findings from the study take things a step further while also explaining DehydraTECH-CBD’s interaction with the sympatho-chromaffin system via catestatin modulation.
In addition, the findings have been published in the respected peer-reviewed journal, “Biomedicine and Pharmacotherapy.” The company is aware of only a handful of other published research studies that have investigated whether a sustained decrease in resting blood pressure (“BP”) is possible following multiple weeks of oral CBD dosing, none of which have been successful in achieving this (https://ibn.fm/qPQYM).
The findings showed that DehydraTECH-CBD resulted in a statistically significant reduction in average baseline serum catestatin concentrations of 13.50 ng/mL to just 9.65 ng/mL after five weeks of dosing, representing a 28.5% drop. In addition, mean arterial pressure significantly dropped by 4.26 ± 1.26 mm/Hg following the five weeks of DehydraTECH-CBD dosing. No statistically significant reductions in catestatin concentrations were identified in the placebo group.
Given the growing demand for alternative anti-hypertensive treatments and therapies, Lexaria recognizes an opportunity and seeks to fill it. These latest results from its ambitious HYPER-H21-4 study inch the company closer to achieving that goal, ultimately becoming a leader and tapping into a pharmaceutical market that is set to be valued at $34 billion by 2030. Lexaria’s management is optimistic that DehydraTECH-CBD and its effectiveness in modulating catestatin levels could become a significant value enhancer should it eventually enter the marketplace as an approved hypertension treatment.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.